One Data and VW Group announce cooperation to solve uneven distribution of critical components
One Data’s AI matching platform Wavetrade allows semiconductors and chips to be exchanged, purchased and sold
Passau, December 8, 2023. German software company One Data today announced a cooperation with German Volkswagen AG (VW), with the aim of counteracting the uneven distribution of critical components. Although global supply chains are under less strain now than in previous months, the situation is still highly imbalanced. The AI-based matching platform Wavetrade solves this problem, as it gives participants access to the surplus stock of critical components held by other partners, meaning semiconductors and chips can be exchanged, purchased and sold.
“Trading critical components without a systematic platform in place is extremely time-consuming. The Wavetrade platform can help to strengthen the liquidity of our suppliers while ensuring the resilience of supply chains and can be seen as a best-practice example of the sharing economy in that it prevents production stops and reduces surplus capacity,” states Karsten Schnake, head of the operative and strategic semiconductor taskforce COMPASS at Volkswagen AG.
By using the platform, participants can boost the resilience of the supply chain, cut back on surplus capacity and optimize their net working capital, improve the sustainability of goods flows, and benefit from the chip inventories of other branches. This is because Wavetrade participants come from various industries – it is not limited solely to the automotive sector.
“A lack of information is largely responsible for disruptions to supply chains and surplus capacities because companies are simply unable to find out if the chips they need are available in the market or if they are required elsewhere. Up to now, this balance could only be redressed in the form of labor-intensive taskforces, and even then purely in the short term and in an unsystematic way. Wavetrade creates transparency and enables to actively counteract,” explains Dr. Stefan Roskos, Managing Director of One Data GmbH.
For further information about Wavetrade please contact us via: www.wavetrade.ai
Please find press material for editorial use in the One Data Press Kit.
Contacts
Maria Große BöckmannSpokesperson One Data GmbH
Tel:+49 (0) 151- 61731953press@onedata.deAbout news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom